Triple therapy shows promise for untreatable liver cancer
NCT ID NCT07081633
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a targeted therapy (lenvatinib) as a first treatment for people with advanced liver cancer that cannot be surgically removed. The study enrolled 114 participants and is active but no longer recruiting. Researchers are measuring how long the cancer stays under control and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab, tremelimumab, and lenvatinib
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with advanced liver cancer that cannot be removed by surgery.
What could go wrong
This is a phase 2 trial with only 114 participants and no comparison group, so results are preliminary. The drug combination may cause serious side effects and may not improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100029, China
-
Research Site
Beijing, 100044, China
-
Research Site
Beijing, 100142, China
-
Research Site
Chengdu, 610078, China
-
Research Site
Chongqing, 400016, China
-
Research Site
Guangzhou, 510060, China
-
Research Site
Guangzhou, 510095, China
-
Research Site
Guangzhou, 510120, China
-
Research Site
Guangzhou, 510515, China
-
Research Site
Hangzhou, 310022, China
-
Research Site
Hefei, 230022, China
-
Research Site
Jinan, 250021, China
-
Research Site
Nanjing, 210009, China
-
Research Site
Nanjing, 210029, China
-
Research Site
Ningbo, 315010, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Shanghai, 200438, China
-
Research Site
Tianjin, 300060, China
-
Research Site
Wenzhou, 325000, China
-
Research Site
Wuhan, 430030, China
-
Research Site
Xiamen, 361004, China
-
Research Site
Zhengzhou, 450052, China
-
Research Site
New Territories, Hong Kong